Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an ...

The administration of U.S. President Donald Trump continues to ramp up the pressure on American universities and scientific ...

AI offers promise in the realm of chronic disease management, including diabetes, obesity, and PCOS, but must be approached with caution.

That’s exactly what Defiance, Ohio is – the weekend getaway you didn’t know you needed. Nestled at the confluence of the Maumee and Auglaize Rivers in Northwest Ohio, Defiance is the kind of place ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Patients were treated with MIPLYFFA in a 48-month open-label extension (OLE) study following the Phase 2/3, randomized, double-blind, placebo-controlled pivotal trial. The OLE data demonstrate that ...

The Motley Fool. DATE Friday, July 18, 2025 at 8 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — William RogersChief Financial Officer — Mike MaguireChief Risk Officer — Brad ...

Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...

INFICON Holding AG (SIX Swiss Exchange: IFCN) will issue on July 30, 2025, a press release at 07:00 a.m. CEST on the second quarter and first-half year 2025 results. At the same time, the accompanying ...

A groundbreaking trial in the U.K. has released data on eight babies born through a special IVF procedure to lower their risk of mitochondrial DNA disease.

Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.

ScientiFix, our weekly feature, offers you a summary of the top global science stories of the week, with links to their ...